Zevorcabtagene autoleucel is under clinical development by CARsgen Therapeutics and currently in Phase II for Relapsed Multiple Myeloma. According to GlobalData, Phase II drugs for Relapsed Multiple Myeloma have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Zevorcabtagene autoleucel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Zevorcabtagene autoleucel overview
CT053 is under development for the treatment of relapsed and refractory multiple myeloma. It is administered through intravenous route. The therapeutic candidate comprises T cells engineered to express chimeric antigen receptor (CAR) with antibody fragment targeting B-cell maturation protein (BCMA/CD269/TNFRSF17) fused to signalling domains transduced lentivirally. It is developed based on CAR-T cell technology.
CARsgen Therapeutics overview
CARsgen Therapeutics (CARsgen) operates as a clinical-stage immune-oncology company focused on developing Chimeric Antigen Receptor T cell therapies for cancer. Its pipeline product includes CAR-GPC3-T for the treatment of late-stage hepatocellular carcinoma (HCC) and lung squamous cell carcinoma; CAR-EGFR targeting Glioblastoma (GBM); CAR-CD19-T against lymphoma and B cell leukemia; CAR-Claudin18.2-T for gastric and pancreatic cancers; and CAR-BCMA-T against multiple myeloma. The company works in strategic partnerships with Shanghai Cancer Institute, Renji Hospital and Changhai Hospital. CARsgen is headquartered in Shanghai, China.
For a complete picture of Zevorcabtagene autoleucel’s drug-specific PTSR and LoA scores, buy the report here.